Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17899378 | 0.92 | BRD4 (0.46) | BRD4LMNASMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL17888598 | 0.85 | PARP10 (0.38) | SMN1; SMN2PDE4DPARP10PDE4APDE4B | |
| SCHEMBL17899128 | 0.82 | PDE4D (0.37) | SMN1; SMN2PDE4DPARP10PDE4APDE4B | |
| SCHEMBL17888597 | 0.82 | PDE4D (0.37) | SMN1; SMN2PDE4DPARP10PDE4APDE4B | |
| SCHEMBL17888594 | 0.82 | PDE4D (0.37) | SMN1; SMN2PDE4DPARP10PDE4APDE4B | |
| SCHEMBL17899405 | 0.82 | KDM4E (0.40) | SMN1; SMN2PDE4DPARP10PDE4APDE4B | |
| SCHEMBL17888615 | 0.82 | PDE4D (0.38) | PDE4DPARP10PDE4APDE4BPDE4C | |
| SCHEMBL17888612 | 0.81 | PDE4D (0.39) | PDE4DPARP10PDE4APDE4BPDE4C | |
| SCHEMBL17899369 | 0.81 | SLC6A2 (0.38) | SMN1; SMN2PDE4DPARP10PDE4APDE4B | |
| SCHEMBL17899127 | 0.81 | CHEK2 (0.38) | PDE4DPARP10PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013728-B2 | Cyclin-dependent kinase 8 and/or 19 inhibitor | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| EP-3607944-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040329-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2016-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | SOST, BMP2, ALPI | BRD4 1976/4885LMNA 3445/4885SMN1; SMN2 2629/4885 |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | CCNI, CDK9, CDK8 | BRD4 216/4885LMNA 2746/4885SMN1; SMN2 4397/4885 |
| US-11013728-B2 | Cyclin-dependent kinase 8 and/or 19 inhibitor | CCNI, CDK9, CDKN1A | BRD4 256/4885LMNA 2411/4885SMN1; SMN2 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.